<div markdown='1'>

**Pulliam, JRC**, **SE Bellan** [p], M Gambhir, LA Meyers, and **J Dushoff**. (2015) Evaluating Ebola vaccine trials: insights from simulation. _**The Lancet Infectious Diseases**_ 15(10): 1134. doi:10.1016/S1473-3099(15)00303-5

**Bellan, SE** [p], **JRC Pulliam**, CAB Pearson [p], D Champredon [g], SJ Fox [g], L Skrip [p], AP Galvani, M Gambhir, BA Lopman, **TC Porco**, LA Meyers, and **J Dushoff**. (2015) Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. _**The Lancet Infectious Diseases**_ 15(6): 703-710. doi: 10.1016/S1473-3099(15)70139-8.

**Bellan, SE** [p], **J Dushoff**, AP Galvani, LA Meyers. (2015) Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts. _**PLoS Medicine**_ 12(3): e1001801. doi: 10.1371/journal.pmed.1001801

**Bellan, SE** [p], **JRC Pulliam**, **J Dushoff**, and LA Meyers. (2014) Ebola control: effect of asymptomatic infection and acquired immunity. _**The Lancet**_ 384(9953): 1499-1500. doi: 10.1016/S01406736(14)618390

**Bellan, SE** [p], **JRC Pulliam**, **J Dushoff**, and LA Meyers. (2014) Ebola vaccine trials: the ethical mandate for a therapeutic safety net. _**The British Medical Journal**_ 349: g7518. doi: http://dx.doi.org/10.1136/bmj.g7518

</div>
